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Koumine enhances spinal cord 
3α-hydroxysteroid oxidoreductase expression 
and activity in a rat model of neuropathic pain
Hong‑Qiang Qiu1†, Ying Xu1,2†, Gui‑Lin Jin1, Jian Yang1,2, Ming Liu1, Su‑Ping Li1 and Chang‑Xi Yu1*
Abstract 
Background: Koumine is an alkaloid monomer found abundantly in Gelsemium plants. It has been shown to reverse 
thermal hyperalgesia and mechanical allodynia induced by sciatic nerve chronic constriction injury (CCI) in rats in a 
dose‑dependent manner. Interestingly, this effect is mediated by elevated allopregnanolone levels in the spinal cord 
(SC). Since 3α‑hydroxysteroid oxidoreductase (3α‑HSOR), the key synthetase of allopregnanolone, is responsible for 
allopregnanolone upregulation in the SC, the objective of the present study was to investigate the role of its expres‑
sion in the SC in koumine‑induced analgesia using a rat model of neuropathic pain following peripheral nerve injury.
Results: Time‑course investigations of immunohistochemistry and real‑time polymerase chain reaction revealed 
that the immunoreactivity and mRNA expression of 3α‑HSOR markedly increased in a time‑dependent manner in 
the SC of koumine‑treated CCI rats. Furthermore, 3α‑HSOR activity in the SC of koumine‑treated CCI rats increased by 
15.8% compared to the activity in untreated CCI rats. Intrathecal injection of medroxyprogesterone acetate, a selective 
3α‑HSOR inhibitor, reversed the analgesic effect of koumine on CCI‑induced mechanical pain perception. Our results 
confirm that koumine alleviates neuropathic pain in rats with CCI by enhancing 3α‑HSOR mRNA expression and 
bioactivity in the SC.
Conclusion: This study demonstrates that 3α‑HSOR is an important molecular target of koumine for alleviating neu‑
ropathic pain. Koumine may prove a promising compound for the development of novel analgesic agents effective 
against intractable neuropathic pain.
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Background
Neuropathic pain is pain resulting from an injury or 
disease of the somatosensory system [1]. A wide vari-
ety of insults to the peripheral and central nervous sys-
tems, including cerebrovascular accident, chemotherapy, 
nutritional deficiencies, surgery, systemic diseases, and 
trauma, can result in neuropathic pain. Neuropathic pain 
can cause abnormal pain sensations, including allodynia, 
hyperalgesia, dysesthesia, and spontaneous pain, which 
are difficult to treat. Current pharmacologic therapy 
for neuropathic pain consists mainly of nonsteroidal 
anti-inflammatory drugs (NSAIDs), opioid analgesics, 
anticonvulsants, antidepressants, and topical remedies. 
Unfortunately, the treatments available for neuropathic 
pain are far from satisfactory: nearly two-thirds of 
patients experiencing neuropathic pain receive insuffi-
cient relief [2]. Therefore, novel analgesics may contrib-
ute to the development of effective treatment strategies 
against neuropathic pain.
Gelsemium is a genus of the family Loganiaceae; it 
comprises 3 species: (1) Gelsemium elegans Benth. 
(Fig.  1), native to Asia; (2) Gelsemium sempervirens 
Ait.; and (3) Gelsemium rankinii Small., native to North 
America [3, 4]. An increasing body of evidence indi-
cates that alkaloidal extracts from G. elegans Benth. elicit 
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numerous biological effects, including analgesic, antide-
pressant, anxiolytic, and antitumor effects [5–9]. G. ele-
gans Benth. has long been used in Chinese folk medicine 
to alleviate pain, inflammation, and cancer [9]. Consist-
ently, alkaloids of G. elegans Benth. are thought to have 
analgesic properties and exhibit pharmaceutical potential 
[10, 11]. The most abundant alkaloid in G. elegans Benth. 
is koumine (molecular formula, C20H22N2O; molecu-
lar weight, 306.30; CAS registry number, 1358-76-5) 
(Fig.  1). According to our previous behavioral observa-
tions in animals, koumine reverses chronic constriction 
injury (CCI) to the sciatic nerve and thermal hyperalgesia 
induced by lumbar 5 (L5) spinal nerve ligation (SNL) in a 
dose-dependent manner. Furthermore, mechanical allo-
dynia in rats is reduced by koumine in a dose-dependent 
manner [12]. Koumine differs substantially from the cur-
rently available analgesics, since it belongs to a class of 
chemicals known as indole alkaloids. Moreover, it lacks 
the adverse effects associated with most analgesic agents 
[6, 11]. Therefore, we hypothesized that the analgesic 
profile and underlying mechanism by which koumine 
induces analgesia are unique.
Allopregnanolone, also known as 3α, 
5α-tetrahydroprogesterone (3α, 5α-THP), is one of the 
most important neuroactive steroids. Upregulation of 
allopregnanolone was shown to induce significant anal-
gesia, implying that allopregnanolone in the spinal cord 
(SC) may be an important key modulator of neuropathic 
pain. Interestingly, our previous work has demonstrated 
that increased allopregnanolone levels in the SC medi-
ated the analgesic effect of koumine on neuropathic 
pain [12]. Although allopregnanolone has been found 
to be upregulated in the SC of rats with CCI following 
koumine treatment, little is known about the cellular and 
molecular mechanisms underlying its antinociceptive 
actions. Since allopregnanolone biosynthesis is depend-
ent on the activity of 3α-hydroxysteroid oxidoreduc-
tase (3α-HSOR), we performed molecular time-course 
experiments to analyze 3α-HSOR’s cellular distribution, 
gene expression, and bioactivity in the lumbar SC follow-
ing koumine treatment of CCI-induced pain symptoms. 
The aim of this study was to investigate the relationship 
between the analgesic effect of koumine on neuropathic 
pain and 3α-HSOR in SC after peripheral nerve injury in 
rats to clarify koumine’s analgesic mechanism of action.
Results
The effect of koumine on CCI‑induced neuropathic pain 
in rats
We have previously demonstrated that koumine has no 
effects in sham CCI rats [12]. In the current study, two-
way repeated measures ANOVA of the thermal withdrawal 
latency (TWL) and mechanical withdrawal threshold 
(MWT) measurement values of the hind paw ipsilateral 
to the CCI demonstrated a significant treatment effect 
between subjects (F5,210 = 1,463.57, P < 0.001 for TWL and 
F5,210 =  167.03, P < 0.001 for MWT) and treatment time 
(F6,210 = 1,816.41, P < 0.001 for TWL and F6,210 = 451.51, 
P < 0.001 for MWT). Furthermore, a significant interaction 
was found between treatment and time (F30,210 =  171.84, 
P < 0.001 for TWL and F30,210 = 36.35, P < 0.001 for MWT). 
Analysis with post hoc Dunnett’s T3 tests indicated that 
CCI significantly decreased the thermal withdrawal latency 
to thermal stimulation (P < 0.001, vs. the sham group) and 
the mechanical withdrawal threshold to mechanical stimu-
lation (P < 0.001, vs. the sham group). These findings dem-
onstrated that the development of thermal hyperalgesia 
and mechanical allodynia peaked on postoperative day 8 
and 10, respectively. Furthermore, both conditions per-
sisted for the entire observation period.
In these experiments, gabapentin [40  mg  kg−1  body 
weight (bw)] significantly attenuated thermal hyperalgesia 
(P < 0.001) and mechanical allodynia (P < 0.05) compared 
to the effect of the vehicle. Twice-daily subcutaneous (s.c.) 
administration of koumine (7 mg kg−1 bw) between post-
operative day 4 and 10 also significantly reversed ther-
mal hyperalgesia (P  <  0.001) and mechanical allodynia 
(P < 0.01) compared to the effect of the vehicle. Interest-
ingly, koumine exhibited more potent suppression of 
thermal hyperalgesia (P < 0.01) and mechanical allodynia 
(P  <  0.01) than was observed for gabapentin. Koumine 
exerted dose-dependent (two-way repeated meas-
ures ANOVA, F2,105  =  290.07, P  <  0.001 for TWL and 
F2,105 = 424.15, P < 0.001 for MWT) and time-dependent 
(two-way repeated measures ANOVA, F6,105  =  1,666.7, 
P < 0.001 for TWL and F2,105 = 22.34, P < 0.001 for MWT) 
analgesic effects. As shown in Fig. 2, koumine administra-
tion (7 mg kg−1 bw, s.c.) induced analgesia within 2 days. 
Fig. 1 Chemical structure of koumine. The chemical structure of 
koumine. Molecular formula, C20H22N2O; molecular weight, 306.40; 
CAS registry number, 1358‑76‑5.
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The maximum analgesic effect was reached on day 7 of 
treatment, and was maintained for 2 days after koumine 
withdrawal. Together, these findings suggest that koumine 
may reverse neuropathic pain.
The effect of koumine on 3α‑HSOR immunoreactivity 
in the dorsal horn of L5–L6 SC of rats with CCI neuropathy
We previously determined that elevated levels of 
allopregnanolone, a neurosteroid present in the SC, 
mediated the analgesic effect of koumine [12]. To further 
investigate the exact mechanism of allopregnanolone 
upregulation, the spinal distribution of 3α-HSOR, the 
key synthetase of allopregnanolone, was assessed by 
fluorescence immunohistochemistry in koumine-treated 
CCI rats. The immunoreactivity of 3α-HSOR in the 
dorsal horn of L5–L6 SC ipsilateral to CCI is shown in 
Fig. 3a. A two-way ANOVA performed on the 3α-HSOR 
fluorescence density data revealed a significant treat-
ment effect between subjects (F4,100 = 61.21, P < 0.001) 
and that 3α-HSOR fluorescence density significantly 
changed with treatment time (F3,100 = 11.35, P < 0.001). 
Furthermore, there was a significant interaction between 
treatment and time (F12,100 = 3.53, P < 0.001). Bonferroni 
post hoc test revealed that CCI treatment significantly 
increased 3α-HSOR immunofluorescence staining den-
sity (P  <  0.001 vs. the sham group) from postoperative 
day 7 to the end of the observation period. In contrast 
to the findings in the CCI group, the treatment- and 
surgery-naïve (“naïve”) and sham groups showed no 
changes in 3α-HSOR immunofluorescence density dur-
ing the entire observation period. Twice-daily admin-
istration of koumine (7 mg kg−1 bw s.c.) between day 4 
and 10 further increased 3α-HSOR immunofluorescence 
staining density, reaching a maximum after 7 consecu-
tive days of treatment (P < 0.001 vs. the vehicle group). 
As shown in Fig.  3b, no differences in dorsal horn 
3α-HSOR immunofluorescence density were observed 
between the CCI and koumine-treated group on postop-
erative day 14 (4 days after koumine withdrawal). Using 
immunofluorescence double labeling we found that 
3α-HSOR was widely distributed in the dorsal horn of 
the SC, and was co-expressed mainly with neurons and 
microglia (Fig. 4).
The effect of koumine on 3α‑HSOR mRNA expression in the 
dorsal horn of rat L5–L6 SC after CCI‑induced neuropathic 
pain
Since 3α-HSOR immunostaining in the dorsal horn 
of the SC of CCI rats was increased after koumine 
administration, we determined lumbar 3α-HSOR 
mRNA expression by reverse transcription polymer-
ase chain reaction (RT-PCR) in the same koumine-
treated CCI rats. Spinal RNA was extracted and its 
integrality and concentration were determined. A 
two-way ANOVA performed on 3α-HSOR mRNA 
expression in the SC ipsilateral to CCI also demon-
strated a significant treatment effect between sub-
jects (F4,100  =  75.89, P  <  0.001) and treatment time 
(F3,100 = 18.34, P < 0.001), and a significant interaction 
between treatment and time (F12,100 = 4.72, P < 0.001) 
(Fig. 5). In agreement with the results of the immuno-
chemistry analysis, Bonferroni post hoc test showed 
Fig. 2 The effects of a repeated subcutaneous administra‑
tion of koumine in sciatic nerve chronic constriction injury rats. 
Koumine (0.28, 1.4, or 7 mg kg−1 body weight (bw)), gabapentin 
(40 mg kg−1 bw), or vehicle was administered twice daily for 7 con‑
secutive days, starting on postoperative day 4. The time course of the 
effect of koumine on the thermal withdrawal latency (TWL, a) and 
mechanical withdrawal threshold (MWT, b) revealed that repeated 
subcutaneous (s.c.) injections of koumine dose‑dependently 
reversed hyperalgesia and allodynia induced by sciatic nerve chronic 
constriction injury (CCI) neuropathy. The data are presented as the 
mean ± SEM (n = 6 per group) and were analyzed using two‑way 
repeated measures ANOVA. The significant differences between 
the groups were determined by Bonferroni post hoc test at each 
time point. ###P < 0.001 vs. the sham group; *P < 0.05, **P < 0.01, 
***P < 0.001 vs. the vehicle control group.
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Fig. 3 3α‑Hydroxysteroid oxidoreductase immunohistochemical staining in the spinal cord of koumine‑treated sciatic nerve chronic constriction 
injury rats. a 3α‑Hydroxysteroid oxidoreductase (3α‑HSOR) immunohistochemical staining in the ipsilateral dorsal horn of the lumbar spinal cord 
(SC, L5–L6). Scale bar 100 μm. b Quantification of the 3α‑HSOR expression in the SC after chronic constriction injury (CCI) by fluorescence density 
analysis. A time‑dependent increase in 3α‑HSOR fluorescence density was observed within the ipsilateral SC dorsal horn after CCI. The data are 
presented as the means ± SEM from 5 to 7 rats per group and were analyzed using two‑way ANOVA followed by Bonferroni post hoc test at each 
time point. ##P < 0.01 vs. the sham group; *P < 0.05 vs. the CCI group.
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that CCI significantly enhanced 3α-HSOR mRNA 
expression (P  <  0.001 vs. sham group) from postop-
erative day 7 to the end of the observation period. In 
contrast, the naïve and sham groups showed no dif-
ference in 3α-HSOR mRNA expression during the 
observation period (P  >  0.05, vs. the CCI group). 
Twice-daily administration of koumine (7 mg kg−1 bw, 
s.c.) between postoperative day 4 and day 10 further 
increased 3α-HSOR mRNA expression and reached 
a maximum after 7 consecutive days of treatment 
(P  <  0.05 vs. the CCI group). However, as shown in 
Fig.  5, compared to the 3α-HSOR mRNA expression 
in the CCI group, koumine-treated rats demonstrated 
a noticeable 3α-HSOR mRNA expression upregula-
tion on postoperative day 14, i.e., 4 days after koumine 
withdrawal (P < 0.05).
The effect of koumine on 3α‑HSOR catalytic activity in rat 
SC after CCI‑induced neuropathic pain
The effect of koumine on spinal 3α-HSOR activity in CCI 
rats was determined by enzyme kinetics analysis. A sig-
nificant treatment effect on the 3α-HSOR catalytic activ-
ity was observed between the rats (one-way ANOVA, 
F4,25 =  19.19, P  <  0.001). As shown in Fig.  6, 3α-HSOR 
activity was significantly increased by 17.4% in CCI rats 
(P < 0.05 vs. the sham group). After 7 consecutive days of 
koumine administration (7  mg  kg−1 bw, s.c.), 3α-HSOR 
activity in the SC of CCI rats was further enhanced by 
15.8% (P < 0.05 vs. the CCI group). This finding implies 
that the increased 3α-HSOR mRNA expression and 
immunostaining in the SC of koumine-treated CCI rats 
may enhance 3α-HSOR bioactivity and upregulate allo-
pregnanolone in the SC.
Fig. 4 Immunostaining of the nerve cellular distribution of 3α‑hydroxysteroid oxidoreductase in the dorsal horn of rat spinal cord. Left (nerve cells): 
Photomicrograph of the dorsal horn section labeled with anti‑neuronal nuclei (NeuN), anti‑ionized calcium binding adaptor molecule 1 (Iba1), and 
anti‑glial fibrillary acidic protein (GFAP) antibody (green). Center (3α‑HSOR): The same section was labeled with anti‑3α‑hydroxysteroid oxidoreduc‑
tase (3α‑HSOR) antibody (red). Right (merged): Photomicrograph of the same section labeled with anti‑3α‑HSOR antibody and either anti‑NeuN, 
anti‑Iba1, or anti‑GFAP antibody. Scale bar 5 μm.
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The effect of medroxyprogesterone acetate on the 
analgesic effect of koumine in mechanical allodynia tests 
in CCI rats
We used the 3α-HSOR inhibitor medroxyprogesterone 
acetate (MPA, administered by intrathecal injection) to 
confirm the hypothesis that the enhanced expression and 
activity of 3α-HSOR, which increase allopregnanolone 
levels in the SC of koumine-treated CCI rats, medi-
ates analgesia. As shown in Fig. 7, the MWT in the hind 
paw ipsilateral to the CCI revealed a significant inter-
group treatment effect (F5,30 = 9.496, P < 0.001, one-way 
ANOVA). Furthermore, s.c.-injected koumine signifi-
cantly relieved mechanical allodynia compared to the 
effect of the vehicle (dimethyl sulfoxide + normal saline, 
DMSO +  NS) group (P  <  0.05). Conversely, intrathecal 
injection of MPA dose-dependently reversed the analge-
sic effect of koumine (F2,15 = 14.511, P < 0.001). MPA (0.5 
and 1.25  mg  kg−1  bw) significantly reduced the MWT 
(P  <  0.001 vs. the DMSO +  koumine group). However, 
the highest dose of MPA tested (1.25  mg  kg−1  bw) had 
no effect on the MWT of untreated CCI rats (P  >  0.05 
vs. the DMSO + NS group). These data suggest that the 
analgesic effect of koumine may be linked to increased 
3α-HSOR activity in the SC.
Discussion
Gelsemium elegans Benth. has diverse biological effects; 
however, its clinical use is hampered by its toxicity. The 
crude alkaloid Gelsemium extract exhibits a high level 
of toxicity with an LD50 of 15 and 4 mg kg−1 bw follow-
ing intragastric and intraperitoneal (i.p.) administra-
tion, respectively, in rats [13]. Several research groups 
are currently trying to derive alkaloid monomers with 
high potency and low toxicity from G. elegans Benth. 
In a previous study, we were able to obtain several dif-
ferent alkaloid monomers using the pH-zone–refining 
counter-current chromatography technique [14], which 
enabled us to perform pharmacodynamic screening. Our 
preliminary findings suggested that the most toxic alka-
loid derived from G. elegans Benth., gelsenicine, exerted 
analgesic activity during inflammatory and neuropathic 
pain [5]. Recently, Zhang et al. reported that gelsemine, 
another G. elegans Benth.-derived main alkaloid, dis-
played potent and specific antinociceptive properties in 
chronic pain [15]. Furthermore, we previously demon-
strated that koumine exhibited potent analgesic effects 
with a relatively low toxicity compared to that of other G. 
elegans Benth. alkaloid extracts [12, 16]. Koumine’s acute 
toxicity was previously investigated in both mice and 
rats. The LD50 of s.c.-administered koumine to mice was 
Fig. 5 The effect of koumine on 3α‑hydroxysteroid oxidoreductase 
mRNA expression in the spinal cord of sciatic nerve chronic constric‑
tion injury rats. The 3α‑hydroxysteroid oxidoreductase (3α‑HSOR) 
mRNA level is expressed as the ratio of glyceraldehyde‑3‑phosphate 
dehydrogenase (GAPDH) mRNA in the spinal cord (SC) of naïve, sham‑
operated, sciatic nerve chronic constriction injury (CCI), or koumine‑
treated rats. The data are presented as the mean ± SEM (n = 6 per 
group) and were analyzed by two‑way ANOVA followed by Bonferroni 
post hoc test at each time point. ##P < 0.01 vs. the sham group; 
*P < 0.05 vs. the CCI group.
Fig. 6 The effect of koumine on 3α‑hydroxysteroid oxidoreductase 
catalytic activity in the spinal cord of sciatic nerve chronic constric‑
tion injury rats. The 3α‑hydroxysteroid oxidoreductase (3α‑HSOR) 
catalytic activity in the spinal cord (SC) lumbar region L5–L6 was 
assessed spectrophotometrically by measuring the oxidation rate of 
nicotinamide adenine dinucleotide phosphate (NADPH) at 340 nm 
and 37°C. The data are presented as the mean ± SEM (n = 6 per 
group) and were analyzed by one‑way ANOVA followed by Bonferroni 
post hoc test at each time point. *P < 0.05 vs. the CCI group, #P < 0.05 
vs. the sham group.
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99.0 mg kg−1 bw [12]. Acute lethality generally occurred 
within 10  min of s.c. injection in mice, with labored 
respiration and brief coordinated clonic convulsions 
occurring immediately before death [12]. Interestingly, 
koumine’s toxicity is much lower than that of the crude 
G. elegans extract. The LD50 of intragastrically adminis-
tered koumine was 300 mg kg−1 bw in rats (unpublished 
data), a level much higher than that estimated for the 
crude alkaloidal extract (15 mg kg−1 bw) using the same 
administration route [13]. Moreover, in a previous study, 
the spontaneous travel velocity was not affected after 
administration of koumine in mice as determined by 
the spontaneous motor activity test [17], and no adverse 
effects were observed in the rats treated with a range of 
koumine doses (0.28–7 mg kg−1 bw) in the current study. 
The relatively wide therapeutic index of koumine sug-
gests that it may be a promising agent in clinical appli-
cations. In this study, the TWL and MWT behavioral 
data indicated that koumine may ameliorate sciatic nerve 
CCI-induced chronic pain. Repeated administration of 
koumine reversed thermal hyperalgesia and mechanical 
allodynia in a dose-dependent manner in our CCI model. 
Additionally, our previous work has provided evidence of 
koumine’s analgesic effect in a number of animal models 
of pain, including SNL and diabetic-induced neuropathic 
pain [12, 18], indicating a role for koumine in the treat-
ment of peripheral neuropathic pain.
Repeated s.c. administration of koumine was not asso-
ciated with adverse effects commonly associated with 
opioids, such as physical and psychological depend-
ence [19]. Interestingly, LaBuda and Little [20] revealed 
that agents such as gabapentin and morphine com-
pletely or partially reversed tactile allodynia in L5 SNL, 
another animal model of painful peripheral neuropa-
thy. Conversely, indomethacin had no effect. Koumine 
also exhibited positive analgesic effects in the L5 SNL 
model [12]. Taken together, these findings suggest that 
koumine’s analgesic mechanism of action differs from 
that of NSAIDs and opioids. Interestingly, we found that 
koumine exhibited its analgesic effect by upregulating 
allopregnanolone, one of the most potent neurosteroids 
in the SC [12].
The pathophysiology underlying neuropathic pain is 
complicated, with many aspects remaining unclear. A 
striking finding in the past three decades was the dis-
covery that neurons are capable of synthesizing neu-
rosteroids independently of the classical mechanism 
involving endocrine glands [21, 22]. The involvement of 
endogenous neurosteroids is well established in the area 
of chronic pain modulation [21–25]. Inflammatory and 
neuropathic pain states are associated with the upregu-
lated synthesis of endogenous neurosteroids in the SC, 
such as allopregnanolone and pregnenolone [21, 23, 26]. 
The administration of exogenous allopregnanolone has 
been shown to prevent and suppress oxaliplatin-evoked 
painful neuropathy [25]. Allopregnanolone is an allos-
teric modulator that controls several important neu-
rophysiological mechanisms through its actions on the 
γ-aminobutyric acid A (GABAA) channel [27]. Indeed, 
neurosteroids modulate pain perception by potentiat-
ing the effects at GABAA channels and inhibiting T-type 
calcium channels located in peripheral sensory neu-
rons [23, 28–30]. Furthermore, neurosteroid synthesis 
has been reported in the SC, partly explaining the vital 
role of SC in the control of pain processing. The SC con-
tains key enzymes related to steroid synthesis, includ-
ing cytochrome P450 side chain cleavage enzymes, 
3α-reductase, and 3α-HSOR [22, 23, 31]. Therefore, the 
key cellular and molecular components involved in neu-
rosteroid biosynthesis in the SC may provide potential 
targets that may be useful for the development of novel 
analgesics for the treatment of persevering neuropathic 
pain. Consequently, an increasing number of scientists 
are focusing their research toward the discovery of novel 
neurosteroid-directed analgesics [29, 30, 32–34].
3α-HSOR belongs to the aldo–keto reductase super-
family. It is crucial for the synthesis of neuroactive 
3α-reduced steroids, such as allopregnanolone and 
Fig. 7 The analgesic effect of koumine was reversed in sciatic 
nerve chronic constriction injury rats by intrathecal treatment with 
medroxyprogesterone acetate. Medroxyprogesterone acetate (MPA) 
or dimethyl sulfoxide (DMSO, vehicle) was administered via an 
intrathecal catheter 10 days after sciatic nerve chronic constriction 
injury (CCI) surgery. After 30 min, koumine (7 mg kg−1 bw) or normal 
saline (NS) was administered by subcutaneous (s.c.) injection. The 
mechanical withdrawal threshold (MWT) of the hind paws was meas‑
ured 1 h after completion of the drug or vehicle administration. The 
data are presented as the mean ± SEM (n = 6 per group) and were 
analyzed by one‑way ANOVA followed by Bonferroni post hoc test at 
each time point. *P < 0.05 vs. the DMSO + NS group; #P < 0.05 vs. the 
DMSO + koumine group.
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tetrahydrodeoxycorticosterone, in a reversible man-
ner. The dorsal horn of the SC, a pivotal structure that 
controls pain and nociception, exhibits intense immu-
nostaining of 3α-HSOR [22, 35]. Furthermore, neurons 
and glial cells synthesize various neurosteroids. Our 
double immunolabeling experiments showed 3α-HSOR 
immunostaining in SC neurons, microglia, and astro-
cytes. This prompted us to investigate the relationship 
between koumine and 3α-HSOR and koumine’s effects 
on allopregnanolone upregulation in the SC. The present 
study draws on data generated by different experimen-
tal techniques that clearly show that koumine increases 
the cellular immunoreactivity, gene expression, and bio-
activity of 3α-HSOR in SC during chronic pain. Impor-
tantly, our time-course experiments revealed that the 
koumine-induced upregulation of 3α-HSOR cellular 
immunoreactivity and gene expression correlated with 
the development of neuropathic pain symptoms.
Consistent with these findings, our in  vivo enzy-
matic activity assays revealed that the catalytic activ-
ity of 3α-HSOR in the SC was increased in CCI rats 
after 7  days of koumine treatment. Furthermore, we 
observed that koumine produced significant analge-
sia and dose-dependently reversed the mechanical pain 
thresholds induced by the intrathecal injection of the 
3α-HSOR pharmacological inhibitor MPA at a dose of 
0.5 or 1.25 mg kg−1 bw. It is worth noting that the high-
est dose of MPA used (1.25  mg  kg−1  bw) had no effect 
on the MWT values measured in naïve CCI rats. Thus, 
inhibiting 3α-HSOR activity in the sensory nerve circuit 
of the SC could reverse the analgesic effect of koumine 
in CCI rats. Our findings demonstrate the direct role of 
3α-HSOR in mediating pain modulation and koumine’s 
influence thereon. Therefore, 3α-HSOR may be a fun-
damental molecular target for koumine in the modula-
tion of pain sensation. However, although the 3α-HSOR 
fluorescence density and mRNA expression were still 
elevated on postoperative day 14, the analgesic effect 
had disappeared by then (Figs.  3, 5). One possibility 
is that koumine may regulate the catalytic activity of 
3α-HSOR. Allopregnanolone biosynthesis in the SC may 
thus be insufficient in the absence of koumine because of 
low 3α-HSOR catalytic activity. However, this hypoth-
esis needs to be confirmed by the determination of allo-
pregnanolone levels in the SC on postoperative day 14. 
Another explanation may be that a molecular target 
other than 3α-HSOR, and whose function is also altered 
by koumine, participates in the observed analgesic effect 
of koumine.
The endogenous biosynthesis of neurosteroids is also 
upregulated in the SC during inflammatory and neuro-
pathic pain states [21, 36, 37]. We demonstrated a simi-
lar increase in allopregnanolone and pregnenolone levels 
in CCI rats [12]. The observed increase in allopregna-
nolone levels in CCI rats is consistent with the findings 
of Kawano et  al. in SNL neuropathy [37]. Similarly, we 
found increased immunohistochemical staining, mRNA 
expression, and bioactivity of 3α-HSOR in the SC during 
sciatic nerve CCI-induced chronic pain. On the basis of 
the results of our and other studies, we consider that a 
state of chronic pain in animals is predominantly deter-
mined by two sets of factors. The first includes the pro-
nociceptive mechanisms mediated by neurotransmitters 
supporting the development and maintenance of pain 
symptoms, such as substance P, bradykinin, prostaglan-
din, and histamine. The second group of factors opposes 
the pro-nociceptive processes, and its effects are medi-
ated by endorphins, neurosteroids, and neuroprotec-
tive factors that possess adaptive or antinociceptive 
properties. The latter help the animal to cope with or 
accelerate the recovery from the pathological pain state. 
Consequently, the selective upregulation of the 3α-HSOR 
immunoreactivity, mRNA expression, and bioactivity 
and the 3α-HSOR-induced increase in spinal synthesis of 
endogenous allopregnanolone may represent an intrinsic 
adaptive response to neuropathic pain and elicit benefi-
cial effects against diverse pathological pain symptoms. 
However, these natural or adaptive mechanisms are not 
sufficient to achieve the suppression of pain sensation 
in rats with CCI [21]. As observed in rats with CCI, an 
insufficient increase in 3α-HSOR and allopregnanolone 
levels fails to reverse the development of neuropathic 
pain. Only a sufficient increase in allopregnanolone 
would offer adequate protection against the development 
of neuropathic pain [12, 37]. Allopregnanolone that is 
endogenously formed in the central nervous system sig-
nificantly alters nociception through paracrine and auto-
crine mechanisms [36, 38]. Therefore, koumine and other 
alkaloid extracts of G. elegans Benth. that are capable of 
stimulating allopregnanolone formation in neural net-
works may provide a novel approach for the development 
of analgesic therapies [39].
Our fluorescence immunohistochemistry experi-
ments also revealed that 3α-HSOR was widely distrib-
uted in the SC dorsal horn and co-localized with neural 
and non-neural cells, including neurons and microglia 
(Fig. 4, merged photomicrograph). In recent years, there 
has been a growing consensus that glial cells located in 
the spinal dorsal horn are activated following periph-
eral nerve injury [40–42]. Microglial activation induces 
the release of proinflammatory cytokines, such as 
interleukin-β, tumor necrosis factor-α, and interleukin-6, 
which play important roles in the development of neuro-
pathic pain. The protective property of allopregnanolone 
in pain perception in relation to glial cells has been well 
documented [25, 34, 43]. Allopregnanolone treatment 
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not only significantly reduced astrocyte proliferation 
and microglial activation, but also enhanced myelination 
in mice [44]. Neurosteroids, such as allopregnanolone, 
could reduce inflammatory cytokine levels, which were, 
for example, elevated following traumatic brain injury 
[45]. Our findings demonstrated that koumine adminis-
tration increased 3α-HSOR activity, which could contrib-
ute to increased allopregnanolone levels in the SC of CCI 
rats. Consequently, we hypothesized that elevated allo-
pregnanolone levels may exert analgesic effects through 
allosteric modulation of GABAA and by suppressing the 
release of microglia activation-induced inflammatory 
cytokines. Further studies are warranted to determine 
whether koumine influences the activation of glial cells 
during the neuropathic pain state.
Conclusion
This study demonstrated that koumine could relieve neu-
ropathic pain in rats by enhancing the mRNA expression 
and bioactivity of 3α-HSOR in the SC. Our study also 
suggested that by targeting 3α-HSOR, koumine altered 
3α-HSOR-regulated allopregnanolone levels in the SC of 
rats. Therefore, koumine may be promising in the search 




Koumine (99% purity) was isolated from G. elegans 
Benth. by pH-zone–refining counter-current chromatog-
raphy as described previously [14]. Gabapentin (purity: 
99%; Shanghai Sunheat Chemicals Co., Ltd, Shanghai, 
China) was used as positive control. Rabbit polyclonal 
antibody against 3α-HSOR was purchased from Bio-
synthesis Biotechnology (Beijing, China) and mouse 
anti-neuronal nuclei monoclonal antibody (anti-NeuN) 
was purchased from GeneTex (Irvine, CA, USA). Goat 
anti-ionized calcium binding adaptor molecule 1  anti-
body (anti-Iba1; catalog no. ab5076) and mouse anti-glial 
fibrillary acidic protein antibody (anti-GFAP; catalog no. 
ab4648) were purchased from Abcam (Cambridge, UK). 
Fluorescein (FITC)-conjugated donkey anti-mouse, tetra-
methylrhodamine (TRITC)-conjugated goat anti-rabbit, 
and Alexa Fluor® 488-conjugated donkey anti-mouse 
were purchased from Jackson ImmunoResearch (West 
Grove, PA, USA). Normal rabbit and donkey serum were 
purchased from Biosynthesis Biotechnology (Beijing, 
China). PCR reagent kits, PrimeScript® RT Reagent Kit, 
and SYBR® Premix Ex Taq™ II Real-Time PCR Reagent 
Kit, were purchased from Takara Biotechnology Co., 
Ltd. (Dalian, China). Nicotinamide adenine dinucleotide 
phosphate-oxidase (NADPH; Roche, Pleasanton, CA, 
USA), 5α-dihydroprogesterone (5α-DHP; Sigma-Aldrich, 
St. Louis, MO, USA), medroxyprogesterone acetate 
(MPA; Selleck, Houston, TX, USA), and chloral hydrate 
(Sigma-Aldrich, St. Louis, MO, USA) were of pharma-
ceutical grade. All other reagents used were of analytical 
grade.
Koumine was prepared daily prior to use in ster-
ile physiological saline (0.9% w/v sodium chloride), 
and was administered by s.c. injection at a dose of 
4 mL kg−1 rat bw.
Animals
Male adult Sprague–Dawley rats (180–200  g) were 
obtained from the Shanghai Laboratory Animal Center 
at the Chinese Academy of Sciences (Shanghai, China). 
All rat experiments were performed in accordance with 
the National Institutes of Health Guide for Care and Use 
of Laboratory Animals (Publication No. 85-23, revised 
1985) and were conducted under the authority of the 
Committee of Ethics of the Fujian Medical University 
(Fujian, China). All procedures complied with the guide-
lines for animal care and use established at the Fujian 
Medical University. The rats were housed in a tempera-
ture-controlled room (25 ± 2°C) under a 12-h light/dark 
cycle (lights on: 08:00 AM), with access to standard labo-
ratory food and water ad libitum, except during behavio-
ral observations. The rats were acclimatized for at least 
1 week before undergoing any experiments. Each rat was 
assigned to one specific behavioral experiment, and the 
experiments were performed between 09:00 and 17:00.
In vivo intrathecal catheter implantation and drug 
administration
Intrathecal implantation of polyethylene (PE) tubing 
(Intramedic PE-10, Clay Adams, Parsippany, NJ, USA) 
into the subarachnoid space of the lumbar enlargement 
was performed in rats as described previously [46]. This 
method permits the direct administration of a drug of 
interest. After 1  day of recovery post surgery, the rats 
that were considered neurologically healthy received 2% 
lidocaine (20 μL) through the intrathecal catheter to con-
firm post-surgical placement of the PE tubing within the 
subarachnoid space. Those rats that displayed complete 
paralysis of both hind limbs and the tail following the 
administration of lidocaine were used for the subsequent 
experiments.
After recovery from intrathecal catheter place-
ment, peripheral neuropathy was induced by CCI. The 
3α-HSOR selective inhibitor MPA was used to evaluate 
the analgesic actions of koumine. The rats undergoing 
mechanical allodynia were assigned to groups receiv-
ing either DMSO (vehicle for MPA) with NS, MPA 
(1.25  mg  kg−1  bw) with NS, DMSO with koumine, or 
MPA (0.25, 0.5, or 1.25 mg kg−1 bw) with koumine. On 
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postoperative (CCI) day 10, DMSO or MPA was adminis-
tered via the intrathecal catheter. After 30 min, koumine 
or NS was administered by s.c. injection. The MWT of 
the hind paws was measured 1 h after completion of the 
drug administration.
Visual confirmation of the placement of the PE tubing 
in the intrathecal space at the lumbar enlargement was 
performed by exposing the lumbar SC at the end of each 
experiment. The data obtained from rats with an incor-
rect PE tubing position were excluded from the study.
Rat CCI model
The rats were prepared for the induction of CCI accord-
ing to the method described by Bennett et  al. [47]. 
The rats were anesthetized by i.p. administration of 
400 mg kg−1 bw chloral hydrate. Subsequently, the right 
common sciatic nerve isolated at the level of the mid-
thigh was loosely ligated using four chromic gut (5-0) ties 
at 1-mm intervals. The same procedure was performed 
without ligation in the rats assigned to the sham group. 
The rats were monitored for 3  days following surgery 
and were only used in the subsequent studies if the base-
line thermal hyperalgesia and mechanical allodynia test 
scores (described in “Measurement of thermal hyperal-
gesia and mechanical allodynia in rats” below) surpassed 
the acceptance threshold. Baseline threshold scores were 
calculated as the CCI ipsilateral paw baseline score/con-
tralateral paw baseline score. Rats displaying baseline 
scores between 0.8 and 1.2 were accepted into the study. 
Rats with thermal predose latency scores >0.8, mechani-
cal predose threshold scores >0.75, and/or demonstrating 
motor deficits after surgery were excluded from the sub-
sequent experiments.
Measurement of thermal hyperalgesia and mechanical 
allodynia in rats
Thermal hyperalgesia was measured with a commer-
cial thermal paw stimulator (PL-200, Chengdu Technol-
ogy & Market Co., Ltd., Sichuan, China) as described by 
Hargreaves et al. [48]. The rats were placed in individual 
plastic cubicles mounted on a glass surface in a tempera-
ture-controlled room (25 ± 2°C). The plantar surface of 
each hind paw was subsequently exposed to a thermal 
stimulus, i.e., radiant heat emitted from a focused projec-
tion bulb, for a maximum exposure time of 16 s to mini-
mize potential tissue damage. The second hind paw of 
each rat was tested after a 10-min interval. The paw TWL 
was calculated as the mean of the 2 hind paw withdrawal 
times.
CCI rats were assigned to groups receiving the vehi-
cle, koumine (0.28, 1.4, or 7.0  mg  kg−1  bw), or gabap-
entin (40  mg  kg−1  bw) twice daily by s.c. injection for 
7 consecutive days starting on postoperative day 4. 
Sham-operated rats underwent identical treatments. 
TWL was measured before surgery (baseline), before 
drug treatment (pre-dosing), and 30  min after drug 
administration (post-dosing) on the morning of postop-
erative day 6, 8, 10, 12, and 14.
Mechanical allodynia was determined with a commer-
cial electronic von Frey apparatus (Model 2390; IITC Life 
Science Inc., Woodland Hills, CA, USA) as described 
by Mitrirattanakul et al. [49], with minor modifications. 
Briefly, the rats were placed in a Plexiglas box on a steel 
mesh floor. The center of the hind paw was stimulated 
using the von Frey filament applied up to a maximum 
strength of 55 g or until the point of paw withdrawal. The 
threshold at which withdrawal occurred was automati-
cally registered. The procedure was performed twice for 
each hind paw at 10-min intervals. The MWT was calcu-
lated as the mean of the 2 thresholds.
The MWT was measured 30 min after the TWL meas-
urement in sham-operated rats and in rats receiving the 
vehicle, koumine (0.28, 1.4, or 7.0 mg kg−1 bw), or gabap-
entin (40 mg kg−1 bw) twice daily by s.c. injection for 7 
consecutive days starting on postoperative day 4.
Immunofluorescence
The rats were assigned to naïve, sham, CCI, CCI with 
7 mg kg−1 bw koumine, and CCI with 0.28 mg kg−1 bw 
koumine groups. Koumine and the vehicle were admin-
istered by s.c. injection at a volume of 0.25 mL/100 g bw 
twice daily for 7 consecutive days starting from postop-
erative day 4. The rats were anesthetized by i.p. injection 
of 400 mg kg−1 bw chloral hydrate 1 h after drug admin-
istration on the morning of postoperative day 5, 7, 10, 
or 14. The L5–L6 of the SC were excised for analysis by 
fluorescence immunohistochemistry as described previ-
ously, with minor modifications [21]. Briefly, 100  mL of 
0.1 M phosphate buffer (PB, pH 7.4) was perfused tran-
scardially followed by perfusion with 450 mL of 4% for-
maldehyde prepared in PB (fixative solution). The SC 
located between L5 and L6 was rapidly dissected and 
fixed in fixative solution for 24  h. The SC tissue was 
immersed in 15% sucrose-containing PB for 12 h and was 
subsequently transferred into 30% sucrose-containing 
PB for 24  h. The SC tissue was then placed in Tissue-
Tek® OCT embedding medium (Sakura, Torrance, CA, 
USA), and was immediately frozen at −22°C. Coronal 
sections (16 μm thick) were cut on a Microm HM 525E 
cryostat (Francheville, France) and were subsequently 
mounted on glass slides coated with gelatin and chro-
mium potassium sulfate.
The SC sections were preincubated for 1  h with the 
following sera in preparation for subsequent immu-
nohistochemical experiments: (1) for mono-labeling 
with anti-3α-HSOR, anti-NeuN, or anti-GFAP, and 
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double-labeling with anti-3α-HSOR and anti-NeuN or 
anti-GFAP, the SC sections were preincubated with 10% 
nonimmune goat serum prepared in PB containing 0.3% 
Triton X-100 (PBT); (2) for mono-labeling with anti-Iba1, 
and double-labeling with anti-3α-HSOR and anti-Iba1, 
the SC sections were preincubated with 10% nonimmune 
donkey serum prepared in PBT.
The immunohistochemical mono-labeling experiments 
were conducted by incubating the SC sections for 24  h 
at 4°C with a single antibody (anti-3α-HSOR, 1:500 dilu-
tion; anti-NeuN, 1:1,000 dilution; anti-Iba1, 1:500 dilu-
tion; anti-GFAP, 1:400 dilution) prepared in PBT. In the 
immunohistochemical double-labeling experiments, the 
sections were incubated with anti-3α-HSOR in combina-
tion with anti-NeuN, anti-Iba1, or anti-GFAP prepared 
in PBT at the same dilution ratios used for the mono 
labeling experiments. After washing for 4 times in phos-
phate-buffered saline (PBS, 5 min per rinse), the sections 
were transferred into a solution containing either a single 
secondary antibody (mono-labeling) or multiple antibod-
ies (double-labeling), and were incubated for 1 h at room 
temperature. The mono-labeling solutions contained 
either TRITC-conjugated goat anti-rabbit, FITC-conju-
gated goat anti-mouse, or FITC-conjugated donkey anti-
goat secondary antibody prepared in PBT at a dilution 
ratio of 1:300. The double-labeling solutions contained 
a mixture of the appropriate two secondary antibodies. 
After rinsing 3 times in PBS (5  min per rinse), the sec-
tions were mounted with anti-fade mounting medium 
(Beyotime, Haimen China), and imaged under a fluores-
cence DMR microscope equipped with a digital camera 
(IX71-A12FL/PH, Olympus, Tokyo, Japan) connected to 
a Pentium 4 PC. The images were adjusted using Pho-
toShop (Version 7; Adobe Systems, Inc., San Jose, CA, 
USA) and the fluorescence density was analyzed using 
the Image-Pro Plus software (Version 6.0; Media Cyber-
netics, Rockville, MD, USA).
Reverse transcription and real‑time PCR
The SC located between L5 and L6 was excised from rats 
anesthetized by i.p. injection of 400 mg kg−1 bw chloral 
hydrate at 5, 7, 10, or 14 days after sciatic nerve ligature 
or the sham procedure. Total RNA was extracted from 
tissue samples using TRIzol reagent (Invitrogen, Carls-
bad, CA, USA) according to the manufacturer’s instruc-
tions. RNA quality was determined by electrophoresis 
using ethidium bromide-stained agarose gels, and was 
further confirmed by an optical density (OD) absorption 
ratio (OD 260 nm/OD 280 nm) >1.7. A fixed quantity of 
total RNA (1 μg) was subjected to reverse transcription 
(RT) PCR performed at 37°C for 15  min. The reaction 
for first-strand cDNA contained the following: 5 ×  Pri-
meScript® Buffer (4 µL), 50 µM Oligo dT Primer (1 µL), 
100 µM random 6 mers (1 µL), PrimeScript® RT Enzyme 
Mix I (1 µL), and total RNA (1 µg) added to RNase Free 
dH2O in a final volume of 20 μL. Real-time PCR (rt-PCR) 
experiments were performed using a LightCycler sys-
tem (Roche Diagnostics GmbH, Mannheim, Germany). 
The primer sequences were as follows: 3α-HSOR sense: 
5′-TTCATTCCTGTACTGGG-3′ and 3α-HSOR anti-
sense: 5′-AGTAGCCTTGATAACTTCAT-3′ [50], glyc-
eraldehyde-3-phosphate dehydrogenase (GAPDH) sense: 
5′-ACCACAGTCCATGCCATCAC-3′ (nucleotides 
3,069–3,088) and GAPDH antisense: 5′-TCCACCAC-
CCTGTTGCTGTA-3′ (nucleotides 3,624–3,605). All 
primers were chemically synthesized by Sangon Biotech 
(Shanghai, China). The housekeeping gene, GAPDH, was 
used as an internal control. The rt-PCR experiments were 
performed in a total volume of 20 μL containing cDNA 
(2 μL), 10 μM specific primers (1.6 μL), and SYBR Pre-
mix Ex Taq (10 μL) containing Taq polymerase, deoxy-
ribonucleotide triphosphate, MgCl2, SYBR Green I dye, 
and dH2O (6.4 µL). A sample without the cDNA template 
(water) was used as a negative control and was run in 
every assay. Each PCR reaction was performed in trip-
licate according to the following amplification protocol: 
a 30-s denaturing step at 95°C, 5-s amplification cycle at 
95°C, 5-s amplification cycle at 55°C, and 12-s amplifica-
tion cycle at 62°C in a total of 45 cycles. The specificity 
of the rt-RT-PCR products and the absence of non-spe-
cific products were confirmed by examining the melting 
curve. The concentration of 3α-HSOR mRNA in each 
sample was determined after normalizing the rt-RT-PCR 
3α-HSOR product to that of GAPDH.
Enzymatic activity assay of 3α‑HSOR
To investigate the enzymatic activity of 3α-HSOR in the 
L5 to L6 region of the SC following koumine administra-
tion, CCI- or sham-operated rats were assigned to vehi-
cle, sham-operated, or koumine (0.28 or 7.0  mg  kg−1 
bw) treatment groups. A naïve group was used as addi-
tional control. Vehicle or koumine was administered by 
s.c. injection twice daily for 7 consecutive days start-
ing on postoperative day 4. On postoperative day 10, 
the rats were euthanized by decapitation, and the SC 
L5 to L6 were rapidly excised and stored at −80°C. 
Enzyme activity assays for 3α-HSOR were performed 
as described previously [51, 52], with minor modifi-
cations. Briefly, 3α-HSOR activity was determined by 
spectrophotometric measurement (UV-2450, Shimadzu, 
Kyoto, Japan) of NADPH oxidation at 340 nm and 37°C 
using a 1.0-cm path length cuvette. The excised SC sec-
tions were homogenized in 2 mL of ice-cold 10 mM PB 
(pH 6.5) containing 0.154  M KCl, 1  mM dithiothrei-
tol, 0.5  mM ethylenediaminetetraacetic acid (EDTA), 
and 1 μM phenylmethanesulfonyl fluoride (PMSF). The 
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homogenate was centrifuged at 105,000×g for 60 min at 
4°C in an Eppendorf 5430R ultracentrifuge (Hamburg, 
Germany). The supernatant (cytosolic) fraction was 
stored at −80°C until required for the enzymatic activ-
ity assay and quantitative analysis. Reductase activity was 
measured in 100  mM  PB (pH 6.5) containing 0.1  mM 
NADPH, 0.08  mM 5α-DHP (substrate), and enzyme 
solution (80 μL of the cytosolic fraction) in a total vol-
ume of 0.7  mL. The reaction was initiated by addition 
of the cofactor to the assay mixture, and a blank sample 
without substrate was included in the measurements. 
The protein concentrations were determined using the 
Enhanced BCA Protein Assay Kit (Beyotime Biotech, 
Haimen, China).
Statistical analysis
Continuous data were expressed as the mean  ±  SEM 
unless otherwise indicated. The TWL and MWT 
responses were analyzed using two-way repeated meas-
ures ANOVA (treatment and time). The significant 
differences between the groups were determined by 
Bonferroni post hoc test. The data from the 3α-HSOR 
catalytic activity and MPA inhibition tests were ana-
lyzed using one-way ANOVA with Bonferroni post hoc 
test. Immunohistochemistry and rtPCR data were ana-
lyzed using two-way ANOVA (treatment and time), fol-
lowed by either Dunnett’s T3 or Bonferroni post hoc 
test. Differences were considered statistically significant 
if P < 0.05. Statistical analyses were performed with the 
Statistical Package for the Social Sciences software (SPSS 
version 13.0; SPSS Inc., Chicago, IL, USA).
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